EGFR is overexpressed in approximately 90% of squamous cell carcinomas of the head and neck [6–8], and more than 80% of NPC patients overexpress EGFR; moreover, its expression is associated with unfavorable T stage and overall survival [9, 10]. Here, EGFR is linked to nasopharyngeal carcinoma.